

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) The use of hyaluronic acid in crosslinked form for the production of a composition for preventing or treating inflammatory skin or mucous membrane diseases.
2. (Original) The use as claimed in claim 1, characterized in that a composition for local administration is produced.
3. (Currently Amended) The use as claimed in claim 1 ~~or 2~~, characterized in that a composition for intradermal administration, for administration to the border of the dermoepithelial transition or for topical administration is produced.
4. (Currently Amended) The use as claimed in ~~one of claims 1 to 3~~ Claim 1, characterized in that the degree of crosslinking is in the range from 0.1% to 10%.
5. (Currently Amended) The use as claimed in ~~one of claims 1 to 4~~ Claim 1, characterized in that the crosslinked hyaluronic acid is present in a mixture with uncrosslinked hyaluronic acid.
6. (Original) The use as claimed in claim 5, characterized in that the uncrosslinked hyaluronic acid is selected from
 - (i) long-chain hyaluronic acid having an average molecular weight (weight-average) of at least 200 kD and
 - (ii) short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD or mixtures thereof.
7. (Currently Amended) The use as claimed in ~~one of claims 1 to 6~~ Claim 1, characterized in that the composition furthermore contains an inhibitor of hyaluronic acid degradation.
8. (Original) The use as claimed in claim 9, characterized in that the inhibitor of hyaluronic acid degradation is selected from heparin, indomethacin, salicylates, free radical traps, such as vitamin A, C or E, and mixtures thereof.
9. (Currently Amended) The use as claimed in ~~one of claims 1 to 8~~ Claim 1, characterized in that the hyaluronic acid is present as an injectable preparation, ointment, cream, lotion, gel, spray, tincture, shampoo, occlusive film, powder or inhalable preparation.
10. (Currently Amended) The use as claimed in ~~one of claims 1 to 9~~ Claim 1, characterized in that the composition furthermore contains another glycosaminoglycan in crosslinked or uncrosslinked form.
11. (Currently Amended) The use as claimed in ~~one of claims 1 to 10~~ Claim 1,

characterized in that the inflammatory skin or mucous membrane disease is selected from atopic dermatitis, eczemas, such as seborrheic and microbial eczemas, pruritus, prurigo, urticaria, red lichen, psoriasis, such as psoriasis vulgaris, vitiligo, viral skin diseases which lead to wart formation, such as verruca vulgaris or Condylomata accuminata, rosacea, perioral dermatitis, acne, such as acne vulgaris or acne conglobata, polypous mucous membrane diseases, such as nasal polyposis, and inflammatory intestinal diseases, chronic or acute ulcerations of the skin, aphthae and mycoses.

12. (Currently Amended) The use as claimed in ~~one of claims 1 to 11~~ Claim 1 in human medicine.

13. (Currently Amended) The use as claimed in ~~one of claims 1 to 11~~ Claim 1 in veterinary medicine.

14. (Original) A process for preventing or treating inflammatory skin or mucous membrane disease, characterized in that a preparation is administered to a subject to be treated, which contains hyaluronic acid in crosslinked form in an amount adequate for treating the disease.

15. (Original) The use of hyaluronic acid in crosslinked form for the production of a composition for preventing or treating inflammatory diseases of the eye.

16. (Original) The use as claimed in claim 15 for preventing or treating inflammatory diseases of the conjunctiva or cornea.

17. (Currently Amended) The use as claimed in claim 15 ~~or 16~~ for preventing or treating after-cataract or inflammation of the conjunctiva.

18. (Currently Amended) The use as claimed in ~~one of claims 15 to 17~~ Claim 15, characterized in that the crosslinked hyaluronic acid is present in a mixture with uncrosslinked hyaluronic acid.

19. (Currently Amended) The use as claimed in ~~one of claims 15 to 18~~ Claim 15, characterized in that the composition furthermore contains another glycos-aminoglycan in crosslinked or uncrosslinked form.

20. (Original) The use of a mixture of crosslinked and un-crosslinked hyaluronic acid for the production of a cosmetic or pharmaceutical composition for treating skin or soft tissue defects and skin wrinkles.

21. (Original) The use as claimed in claim 20, characterized in that the composition furthermore contains another glycos-aminoglycan in crosslinked or uncrosslinked form.